Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.

Garg N, Zhang Y, Nicholson-Weller A, Khankin EV, Borsa NG, Meyer NC, McDermott S, Stillman IE, Rennke HG, Smith RJ, Pavlakis M.

Nephrol Dial Transplant. 2018 Dec 1;33(12):2260-2265. doi: 10.1093/ndt/gfx369.

PMID:
29370420
2.

CR1-mediated ATP release by human red blood cells promotes CR1 clustering and modulates the immune transfer process.

Melhorn MI, Brodsky AS, Estanislau J, Khoory JA, Illigens B, Hamachi I, Kurishita Y, Fraser AD, Nicholson-Weller A, Dolmatova E, Duffy HS, Ghiran IC.

J Biol Chem. 2013 Oct 25;288(43):31139-53. doi: 10.1074/jbc.M113.486035. Epub 2013 Sep 10.

3.

Hematology and diabetes: from hemoglobin A1c to CD59 glycation.

Nicholson-Weller A.

Am J Hematol. 2013 Aug;88(8):633. doi: 10.1002/ajh.23500. Epub 2013 Jul 3. Review. No abstract available.

4.

Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Ogembo JG, Kannan L, Ghiran I, Nicholson-Weller A, Finberg RW, Tsokos GC, Fingeroth JD.

Cell Rep. 2013 Feb 21;3(2):371-85. doi: 10.1016/j.celrep.2013.01.023. Epub 2013 Feb 14.

5.

A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline.

Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative, Allen AN, Corneveaux JJ, Hardy JA, Huentelman MJ, Lemere CA, Myers AJ, Nicholson-Weller A, Reiman EM, Evans DA, Bennett DA, De Jager PL.

Hum Mol Genet. 2012 May 15;21(10):2377-88. doi: 10.1093/hmg/dds054. Epub 2012 Feb 17.

6.

Ligation of complement receptor 1 increases erythrocyte membrane deformability.

Glodek AM, Mirchev R, Golan DE, Khoory JA, Burns JM, Shevkoplyas SS, Nicholson-Weller A, Ghiran IC.

Blood. 2010 Dec 23;116(26):6063-71. doi: 10.1182/blood-2010-04-273904. Epub 2010 Sep 22.

7.

C3b deposition on human erythrocytes induces the formation of a membrane skeleton-linked protein complex.

Karnchanaphanurach P, Mirchev R, Ghiran I, Asara JM, Papahadjopoulos-Sternberg B, Nicholson-Weller A, Golan DE.

J Clin Invest. 2009 Apr;119(4):788-801. doi: 10.1172/JCI36088. Epub 2009 Mar 2.

8.

Complex dynamics of human red blood cell flickering: alterations with in vivo aging.

Costa M, Ghiran I, Peng CK, Nicholson-Weller A, Goldberger AL.

Phys Rev E Stat Nonlin Soft Matter Phys. 2008 Aug;78(2 Pt 1):020901. Epub 2008 Aug 1.

9.

Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1.

Ghiran I, Glodek AM, Weaver G, Klickstein LB, Nicholson-Weller A.

Blood. 2008 Oct 15;112(8):3465-73. doi: 10.1182/blood-2008-04-151845. Epub 2008 Aug 6.

10.

Antibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35).

Chen CH, Ghiran I, Beurskens FJ, Weaver G, Vincent JA, Nicholson-Weller A, Klickstein LB.

Clin Exp Immunol. 2007 Jun;148(3):546-54.

11.

Complement C3a enhances CXCL12 (SDF-1)-mediated chemotaxis of bone marrow hematopoietic cells independently of C3a receptor.

Honczarenko M, Ratajczak MZ, Nicholson-Weller A, Silberstein LE.

J Immunol. 2005 Sep 15;175(6):3698-706.

12.

C5L2 receptor is not involved in C3a / C3a-desArg-mediated enhancement of bone marrow hematopoietic cell migration to CXCL12.

Honczarenko M, Lu B, Nicholson-Weller A, Gerard NP, Silberstein LE, Gerard C.

Leukemia. 2005 Sep;19(9):1682-3; author reply 1684-5. No abstract available.

PMID:
15990859
13.
14.

Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence.

Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC.

Infect Immun. 2005 Jun;73(6):3502-11.

15.

A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1).

Repik A, Pincus SE, Ghiran I, Nicholson-Weller A, Asher DR, Cerny AM, Casey LS, Jones SM, Jones SN, Mohamed N, Klickstein LB, Spitalny G, Finberg RW.

Clin Exp Immunol. 2005 May;140(2):230-40.

16.

A role for lipid rafts in C1q-triggered O2- generation by human neutrophils.

Otabor I, Tyagi S, Beurskens FJ, Ghiran I, Schwab P, Nicholson-Weller A, Klickstein LB.

Mol Immunol. 2004 Jun;41(2-3):185-90.

PMID:
15159064
17.

Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release.

Levy O, Jean-Jacques RM, Cywes C, Sisson RB, Zarember KA, Godowski PJ, Christianson JL, Guttormsen HK, Carroll MC, Nicholson-Weller A, Wessels MR.

Infect Immun. 2003 Nov;71(11):6344-53.

18.

Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule.

Ghiran I, Klickstein LB, Nicholson-Weller A.

J Biol Chem. 2003 Jun 6;278(23):21024-31. Epub 2003 Mar 19.

19.

Expression and function of C1q receptors and C1q binding proteins at the cell surface.

Ghiran I, Tyagi SR, Klickstein LB, Nicholson-Weller A.

Immunobiology. 2002 Sep;205(4-5):407-20. Review.

PMID:
12396003
20.

Into the third century of complement research.

Morgan BP, Daha M, Meri S, Nicholson-Weller A.

Immunol Today. 2000 Dec;21(12):603-5. No abstract available.

PMID:
11188795
21.

Complement receptor 1/CD35 is a receptor for mannan-binding lectin.

Ghiran I, Barbashov SF, Klickstein LB, Tas SW, Jensenius JC, Nicholson-Weller A.

J Exp Med. 2000 Dec 18;192(12):1797-808.

22.
24.

C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.

Tas SW, Klickstein LB, Barbashov SF, Nicholson-Weller A.

J Immunol. 1999 Nov 1;163(9):5056-63.

25.

Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.

Butko P, Nicholson-Weller A, Wessels MR.

J Immunol. 1999 Sep 1;163(5):2761-8.

26.

In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67).

Wang C, Bozza PT, Barbashov SF, Sauty A, Nicholson-Weller A.

Clin Exp Immunol. 1999 Aug;117(2):261-8.

27.

Phylogenetic analysis of the homologous proteins of the terminal complement complex supports the emergence of C6 and C7 followed by C8 and C9.

Mondragón-Palomino M, Piñero D, Nicholson-Weller A, Laclette JP.

J Mol Evol. 1999 Aug;49(2):282-9.

PMID:
10441679
28.

C1q-binding proteins and C1q receptors.

Nicholson-Weller A, Klickstein LB.

Curr Opin Immunol. 1999 Feb;11(1):42-6. Review.

PMID:
10047536
29.

Complement receptor type 1 (CR1, CD35) is a receptor for C1q.

Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A.

Immunity. 1997 Sep;7(3):345-55.

30.

Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement.

Fischer MB, Prodeus AP, Nicholson-Weller A, Ma M, Murrow J, Reid RR, Warren HB, Lage AL, Moore FD Jr, Rosen FS, Carroll MC.

J Immunol. 1997 Jul 15;159(2):976-82.

PMID:
9218619
31.

Serum amyloid P component forms a stable complex with human C5b6.

Barbashov SF, Wang C, Nicholson-Weller A.

J Immunol. 1997 Apr 15;158(8):3830-5.

PMID:
9103450
32.

Role of complement and complement receptor C1qR in the antibody-independent killing of group B streptococcus.

Butko P, Nicholson-Weller A, Wessels MR.

Adv Exp Med Biol. 1997;418:941-3. No abstract available.

PMID:
9331805
33.

Signaling by hemolytically inactive C5b67, an agonist of polymorphonuclear leukocytes.

Wang C, Gerard NP, Nicholson-Weller A.

J Immunol. 1996 Jan 15;156(2):786-92.

PMID:
8543834
34.

Hemolytically inactive C5b67 complex: an agonist of polymorphonuclear leukocytes.

Wang C, Barbashov S, Jack RM, Barrett T, Weller PF, Nicholson-Weller A.

Blood. 1995 May 1;85(9):2570-8.

PMID:
7727785
35.

Regulation of C1q receptor expression on human polymorphonuclear leukocytes.

Jack RM, Lowenstein BA, Nicholson-Weller A.

J Immunol. 1994 Jul 1;153(1):262-9.

PMID:
7911495
36.

Structure and function of decay accelerating factor CD55.

Nicholson-Weller A, Wang CE.

J Lab Clin Med. 1994 Apr;123(4):485-91. Review.

PMID:
7511675
37.
38.

cDNA cloning and recombinant expression of collagen-binding and complement inhibitor activity of Taenia solium paramyosin (AgB).

Landa A, Laclette JP, Nicholson-Weller A, Shoemaker CB.

Mol Biochem Parasitol. 1993 Aug;60(2):343-7. No abstract available.

PMID:
8232426
39.

Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells.

Halperin JA, Taratuska A, Nicholson-Weller A.

J Clin Invest. 1993 May;91(5):1974-8.

40.

Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily.

Ackerman SJ, Corrette SE, Rosenberg HF, Bennett JC, Mastrianni DM, Nicholson-Weller A, Weller PF, Chin DT, Tenen DG.

J Immunol. 1993 Jan 15;150(2):456-68.

PMID:
8419478
41.

Membrane signaling by complement C5b-9, the membrane attack complex.

Nicholson-Weller A, Halperin JA.

Immunol Res. 1993;12(3):244-57. Review.

PMID:
8288945
42.

Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9).

Halperin JA, Taratuska A, Rynkiewicz M, Nicholson-Weller A.

Blood. 1993 Jan 1;81(1):200-5.

PMID:
7678066
43.
44.

Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes.

Mahoney JF, Urakaze M, Hall S, DeGasperi R, Chang HM, Sugiyama E, Warren CD, Borowitz M, Nicholson-Weller A, Rosse WF, et al.

Blood. 1992 Mar 15;79(6):1400-3.

PMID:
1372185
45.

Paramyosin inhibits complement C1.

Laclette JP, Shoemaker CB, Richter D, Arcos L, Pante N, Cohen C, Bing D, Nicholson-Weller A.

J Immunol. 1992 Jan 1;148(1):124-8.

PMID:
1727860
46.

Decay accelerating factor (CD55).

Nicholson-Weller A.

Curr Top Microbiol Immunol. 1992;178:7-30. Review. No abstract available.

PMID:
1385047
47.

Homologous species restriction of the complement-mediated killing of nucleated cells.

Yamamoto H, Blaas P, Nicholson-Weller A, Hänsch GM.

Immunology. 1990 Aug;70(4):422-6.

48.

Phosphatidylinositol-specific phospholipase C, a possible virulence factor of Staphylococcus aureus.

Marques MB, Weller PF, Parsonnet J, Ransil BJ, Nicholson-Weller A.

J Clin Microbiol. 1989 Nov;27(11):2451-4.

49.

Cytoplasmic lipid bodies of human neutrophilic leukocytes.

Weller PF, Ackerman SJ, Nicholson-Weller A, Dvorak AM.

Am J Pathol. 1989 Nov;135(5):947-59.

50.

Factor J: isolation and characterization of a new polypeptide inhibitor of complement C1.

Lopez-Trascasa M, Bing DH, Rivard M, Nicholson-Weller A.

J Biol Chem. 1989 Sep 25;264(27):16214-21.

Supplemental Content

Loading ...
Support Center